Ken Griffin’s Xenetic Biosciences XBIO Stock Holding History

Ken Griffin’s Portfolio XBIO Stock Details XBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,879	Closed	-$32.3K	–	14377
2025 Q4	$32.3K	Buy	+14,879	New	+$47.4K	﹤0.01%	12206
2025 Q2	–	Sell	-17,289	Closed	-$45.1K	–	15387
2025 Q1	$45.1K	Buy	17,289 +3,909	+29%	+$15.3K	﹤0.01%	12411
2024 Q4	$53.9K	Buy	+13,380	New	+$54K	﹤0.01%	12309
2023 Q2	–	Sell	-1,637	Closed	-$6.74K	–	15339
2023 Q1	$6.74K	Sell	1,637 -1,620	-50%	-$7.86K	﹤0.01%	13782
2022 Q4	$9.31K	Buy	+3,257	New	+$14.3K	﹤0.01%	13690
2022 Q1	–	Sell	-5,798	Closed	-$60.5K	–	14715
2021 Q4	$75K	Buy	+5,798	New	+$92.5K	﹤0.01%	12990
2021 Q3	–	Sell	-5,121	Closed	-$104K	–	14765
2021 Q2	$104K	Sell	5,121 -4,079	-44%	-$82.3K	﹤0.01%	12888
2021 Q1	$201K	Buy	+9,200	New	+$242K	﹤0.01%	11695
2019 Q1	–	Sell	-115	Closed	-$22K	–	9948
2018 Q4	$22K	Buy	+115	New	+$34.8K	﹤0.01%	8714
2018 Q2	–	Sell	-97	Closed	-$25K	–	9356
2018 Q1	$25K	Buy	+97	New	+$24.3K	﹤0.01%	8092

Other funds holding XBIO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

DWM

Darwin Wealth Management Tampa, Florida $365M AUM 22.69% 1-Year Est. Return

Ken Griffin's XBIO Position: Q1 2026 in Review

Ken Griffin sold out of Xenetic Biosciences (XBIO) in Q1 2026, closing a stake of 14,879 shares — an estimated $32.3K sold.

Ken Griffin first reported a position in XBIO in Q1 2018 and held it in 10 quarters. The position peaked at $201K in Q1 2021. 6 funds tracked by Wall St. Rank hold XBIO as of Q1 2026.

Ken Griffin reported no remaining Xenetic Biosciences position as of Q1 2026 after selling out during the quarter.
Ken Griffin sold 14,879 Xenetic Biosciences shares in Q1 2026, an estimated $32.3K.
Ken Griffin first reported a position in Xenetic Biosciences in Q1 2018 and held it in 10 quarters.
Ken Griffin's Xenetic Biosciences position peaked at $201K in Q1 2021.
6 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.